Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Background: Biliary tract cancer is one of the most aggressive and fatal tumours. Gemcitabine with cisplatin chemotherapy has long been the first-line treatment, but the prognosis is poor. In recent years, targeted treatment and immunotherapy have produced encouraging outcomes requiring a thorough r...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/1/39 |
| _version_ | 1797626169330237440 |
|---|---|
| author | Xin Yan Huimin Zou Yunfeng Lai Carolina Oi Lam Ung Hao Hu |
| author_facet | Xin Yan Huimin Zou Yunfeng Lai Carolina Oi Lam Ung Hao Hu |
| author_sort | Xin Yan |
| collection | DOAJ |
| description | Background: Biliary tract cancer is one of the most aggressive and fatal tumours. Gemcitabine with cisplatin chemotherapy has long been the first-line treatment, but the prognosis is poor. In recent years, targeted treatment and immunotherapy have produced encouraging outcomes requiring a thorough review and meta-analysis. Method: For this systematic review and meta-analysis, we searched four databases, starting from the inception dates of databases to 11 January 2022. This study comprised randomised clinical trials and cohort studies that used immunotherapy or targeted treatment as the first line of treatment for patients with biliary tract cancer. Results: From the 888 studies extracted, 33 trials were examined and found to meet the criteria. These included 3087 patients, 16 single-arm trials, 13 RCTs, one nRCT, a prospective single-arm pilot study, and a clinical setting in the real world. From 2010 to 2020, 33 studies were conducted using targeted treatment or immunologic therapies as first-line treatments for BTC patients, and 18 of those studies had positive outcomes. Conclusion: This study demonstrates that immunotherapy combined with chemotherapy as first-line treatment can provide survival benefits by improving the objective response rate for patients with unresectable biliary tract cancer. The potential for combination therapy to become a new trend in clinical treatment is promising but needs further clinical evaluation. |
| first_indexed | 2024-03-11T10:06:40Z |
| format | Article |
| id | doaj.art-391cd4cff4254531abc48dfd7aea37ac |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T10:06:40Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-391cd4cff4254531abc48dfd7aea37ac2023-11-16T15:00:46ZengMDPI AGCancers2072-66942022-12-011513910.3390/cancers15010039Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-AnalysisXin Yan0Huimin Zou1Yunfeng Lai2Carolina Oi Lam Ung3Hao Hu4State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, ChinaSchool of Public Health and Management, Guangzhou University of Chinese Medicine, Guangzhou 510006, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, ChinaBackground: Biliary tract cancer is one of the most aggressive and fatal tumours. Gemcitabine with cisplatin chemotherapy has long been the first-line treatment, but the prognosis is poor. In recent years, targeted treatment and immunotherapy have produced encouraging outcomes requiring a thorough review and meta-analysis. Method: For this systematic review and meta-analysis, we searched four databases, starting from the inception dates of databases to 11 January 2022. This study comprised randomised clinical trials and cohort studies that used immunotherapy or targeted treatment as the first line of treatment for patients with biliary tract cancer. Results: From the 888 studies extracted, 33 trials were examined and found to meet the criteria. These included 3087 patients, 16 single-arm trials, 13 RCTs, one nRCT, a prospective single-arm pilot study, and a clinical setting in the real world. From 2010 to 2020, 33 studies were conducted using targeted treatment or immunologic therapies as first-line treatments for BTC patients, and 18 of those studies had positive outcomes. Conclusion: This study demonstrates that immunotherapy combined with chemotherapy as first-line treatment can provide survival benefits by improving the objective response rate for patients with unresectable biliary tract cancer. The potential for combination therapy to become a new trend in clinical treatment is promising but needs further clinical evaluation.https://www.mdpi.com/2072-6694/15/1/39biliary tract cancercholangiocarcinomatargeted therapyimmunotherapy |
| spellingShingle | Xin Yan Huimin Zou Yunfeng Lai Carolina Oi Lam Ung Hao Hu Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis Cancers biliary tract cancer cholangiocarcinoma targeted therapy immunotherapy |
| title | Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis |
| title_full | Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis |
| title_short | Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis |
| title_sort | efficacy and safety of first line targeted treatment and immunotherapy for patients with biliary tract cancer a systematic review and meta analysis |
| topic | biliary tract cancer cholangiocarcinoma targeted therapy immunotherapy |
| url | https://www.mdpi.com/2072-6694/15/1/39 |
| work_keys_str_mv | AT xinyan efficacyandsafetyoffirstlinetargetedtreatmentandimmunotherapyforpatientswithbiliarytractcancerasystematicreviewandmetaanalysis AT huiminzou efficacyandsafetyoffirstlinetargetedtreatmentandimmunotherapyforpatientswithbiliarytractcancerasystematicreviewandmetaanalysis AT yunfenglai efficacyandsafetyoffirstlinetargetedtreatmentandimmunotherapyforpatientswithbiliarytractcancerasystematicreviewandmetaanalysis AT carolinaoilamung efficacyandsafetyoffirstlinetargetedtreatmentandimmunotherapyforpatientswithbiliarytractcancerasystematicreviewandmetaanalysis AT haohu efficacyandsafetyoffirstlinetargetedtreatmentandimmunotherapyforpatientswithbiliarytractcancerasystematicreviewandmetaanalysis |